NX1.AU Nexalis Therapeutics Ltd
- Market cap
- AUD 2.28M
- P/E
- -
- P/B
- 8.55x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 0.5/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is NX1.AU undervalued?
Graham numberThe Graham number of Nexalis Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nexalis Therapeutics Ltd fundamental analysis
2 of 21 checks passedROE 0/2
ROE cannot be calculated: equity is negative or not reported.
ROA 0/1
Return on assets (-113.0%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-20.2%) is below the industry median (-5.3%).
Revenue Growth 2/2
Revenue grew 167.5% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.5 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (8.6x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Nexalis Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nexalis Therapeutics Ltd
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to N…
Full company profileNexalis Therapeutics Ltd financial statements
Nexalis Therapeutics Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 167K | 51.9K | 1.21M | 405K | 992K |
| Gross Profit | 52.1K | 51.9K | - | - | - |
| Operating Income | -1.13M | -1.93M | -1.44M | -1.28M | -1.48M |
| EBITDA | - | -1.95M | -1.44M | -1.12M | -1.48M |
| Net Income | -1.11M | -1.93M | -1.44M | -1.21M | -1.62M |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | |||||
| Total Assets | 2.95M | 2.26M | 1.58M | 712K | 1.43M |
| Total Liabilities | 253K | 355K | 911K | 445K | 2.05M |
| Shareholders' Equity | 2.68M | 1.90M | 665K | 267K | -619K |
| Cash & Short-term Investments | 2.80M | 2.13M | 716K | 195K | 437K |
| Cash Flow | |||||
| Operating Cash Flow | - | - | -1.96M | -369K | -888K |
| Capital Expenditure | 25.1K | 175.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.17M | -1.85M | -1.96M | -369K | -888K |
| Ratios | |||||
| ROE | -41.5% | -101.3% | -216.9% | -452.7% | - |
| ROA | -37.6% | -85.3% | -91.5% | -169.8% | -113.0% |
| Net Profit Margin | -664.1% | -3,716.6% | -119.7% | -298.3% | -163.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Nexalis Therapeutics Ltd dividends
Nexalis Therapeutics Ltd has not paid dividends in the last 5 fiscal years.
Who owns Nexalis Therapeutics Ltd
- Insiders 51.64%
- Institutions 0.00%
- Public & others 48.36%
- Shares outstanding 253M
- Free float 79.9M
Nexalis Therapeutics Ltd company profile
- Company name
- Nexalis Therapeutics Ltd
- Ticker
- NX1.AU
- ISIN
- AU0000456733
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 505 Little Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 8678 4091
- Website
- inhalerx.com.au
About Nexalis Therapeutics Ltd
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia.
Nexalis Therapeutics Ltd management
5- Mr. Darryl Davies B.Sc.CEO & Interim Executive Director
- Dr. Robert Jenny B.A., B.Sc., Ph.D.Chief Scientific Officer
- Mr. James Stephen Barrie CPACompany Secretary & Director
- Mr. Greg HammondChief Financial Officer
- Mr. Srinivasa Rao SuryadevaraExecutive Vice President · born 1969